ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
-0.4%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.74B
AUM Growth
+$5.74B
(-0.8%)
Cap. Flow
+$147M
Cap. Flow
% of AUM
2.55%
Top 10 Holdings %
Top 10 Hldgs %
69.13%
Holding
51
New
5
Increased
13
Reduced
8
Closed
7
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$250M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$170M |
| 3 |
Monte Rosa Therapeutics
GLUE
|
$62.2M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$52.5M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$28.6M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$123M |
| 2 |
Travere Therapeutics
TVTX
|
$31.2M |
| 3 |
Relmada Therapeutics
RLMD
|
$18.9M |
| 4 |
PMV Pharmaceuticals
PMVP
|
$18.3M |
| 5 |
Relay Therapeutics
RLAY
|
$17.3M |
Sector Composition
| 1 | Healthcare | 98.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $843M | 14.66% | 9,000,000 | – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $808M | 14.05% | 5,000,000 +325,000 | +7% | +$52.5M |
|
3
United Therapeutics
UTHR
$13.8B
| $538M | 9.36% | 3,000,000 | – | – |
|
|
XLRN
4
DELISTED
Acceleron Pharma Inc.
XLRN
| $376M | 6.55% | 3,000,000 | – | – |
|
5
argenx
ARGX
$43.6B
| $285M | 4.96% | 946,500 +21,000 | +2% | +$6.32M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $278M | 4.83% | 4,075,000 +25,000 | +0.6% | +$1.71M |
|
|
7
Ascendis Pharma
ASND
$11.8B
| $250M | 4.35% | +1,900,000 | New | +$250M |
|
|
8
Iovance Biotherapeutics
IOVA
$807M
| $237M | 4.12% | 9,100,000 +1,100,000 | +14% | +$28.6M |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $187M | 3.25% | 2,400,000 +250,000 | +12% | +$19.4M |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $170M | 2.95% | +1,000,000 | New | +$170M |
|
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $159M | 2.77% | 790,000 -610,000 | -44% | -$123M |
|
12
Madrigal Pharmaceuticals
MDGL
$9.76B
| $139M | 2.41% | 1,425,000 | – | – |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $138M | 2.4% | 1,650,000 | – | – |
|
14
Amicus Therapeutics
FOLD
$2.34B
| $120M | 2.09% | 12,450,000 +200,000 | +2% | +$1.93M |
|
|
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $108M | 1.89% | 3,210,000 +260,000 | +9% | +$8.79M |
|
16
Mersana Therapeutics
MRSN
$36.5M
| $92.3M | 1.61% | 6,800,000 | – | – |
|
17
Kura Oncology
KURA
$686M
| $86.3M | 1.5% | 4,140,000 +140,000 | +4% | +$2.92M |
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $68M | 1.18% | 3,650,000 | – | – |
|
19
Apellis Pharmaceuticals
APLS
$3.48B
| $63.5M | 1.11% | 1,005,230 +5,230 | +0.5% | +$331K |
|
|
20
PMV Pharmaceuticals
PMVP
$74.2M
| $62.3M | 1.08% | 1,825,000 -535,267 | -23% | -$18.3M |
|
|
21
Monte Rosa Therapeutics
GLUE
$296M
| $62.2M | 1.08% | +3,311,434 | New | +$62.2M |
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $59.6M | 1.04% | 2,441,658 -58,342 | -2% | -$1.42M |
|
|
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $58M | 1.01% | 3,235,000 | – | – |
|
|
TRIL
24
DELISTED
Trillium Therapeutics Inc.
TRIL
| $55.3M | 0.96% | 5,700,000 | – | – |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $51.5M | 0.9% | 3,000,000 +500,000 | +20% | +$8.59M |
|